tirzepatide surmount-1 trial weight loss non-diabetic nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes SURMOUNT-1 Trial - Cardionerds Twitter

Feb 2018;61(2):257-264

It has been shown that patients with major depressive disorder have systemic and localized disorders of glucose metabolism throughout the course of the disease, disrupting various processes such as glucose uptake, glycoprotein transport, glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation

Retrieved from Halford, J.C

Key pharmacological characteristics include: Short half-life: Approximately 10-20 minutes Pulsatile stimulation: Mimics the bodys natural GH release pattern Self-limiting mechanism: The pituitarys negative feedback system prevents excessive GH production Peak activity during sleep: When administered before bed, sermorelin enhances the natural nocturnal GH surge A clinical study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that sermorelin administration increased GH secretion and IGF-1 levels in older adults with documented age-related GH decline, with improvements in body composition and sleep quality (Vittone et al., 1997, JCEM )

These reactions are unrelated to time of day but can be minimized through proper injection technique, site rotation, and ensuring medication reaches room temperature before administration